Xinkanghe Biopharmaceutical is involved in the development of XKH001, a monoclonal antibody targeting IL-25, aimed at treating various inflammatory diseases including asthma and chronic obstructive pulmonary disease (COPD)
Xinkanghe Biopharmaceutical is involved in the development of XKH001, a monoclonal antibody targeting IL-25, aimed at treating various inflammatory diseases including asthma and chronic obstructive pulmonary disease (COPD).